RPRXRoyalty Pharma plc
Is it safe?
Strong, no red flags: a safe balance sheet and steady price behavior.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$13.0M, 90 days to Oct 8, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Relatively steady, low volatility. Worst drawdown -50% · now 11% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can RPRX take a bad year?
Royalty Pharma plc carries $8.12B of net debt at 5.36× EBITDA: a heavy load to carry through a bad year.
Net debt · as at Q2 2026 · over four years of earnings before interest, tax and depreciation, heavy
- Net debt / EBITDA
- 5.36×
Net debt / EBITDA
- Altman Z-score
- 2.51
Altman Z-score · grey zone, between 1.8 and 3
- Interest cover
- 4.19×
Interest cover · operating profit covers the interest bill, with room to spare
Details›
- Total debtQ2 2026
- $8.96B
- Cash and short-term investments
- $837M
- Net debt
- $8.12B
- EBITDA, trailing twelve months
- $1.52B
- Operating profit, trailing twelve months
- $1.51B
- Debt / equity
- 0.92×
- Total debt / EBITDA
- 5.91×
- Annualised volatilitytwo years of daily moves
- 24%
- Worst drawdown on file
- −50%
- Below its 52-week high
- 11%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.